Patna: Bharat Biotech has started paediatric trials of its COVID-19 vaccine Covaxin at the All India Institute of Medical Sciences (AIIMS) Patna.
The Drugs Controller General of India last month approved clinical trials of Covaxin among children and teenagers aged 2 to 18 years.
Trials on children will be carried out on 525 subjects at various sites, including AIIMS Delhi.
“The vaccine is developed using Whole-Virion Inactivated Vero Cell derived platform technology. Inactivated vaccines do not replicate and are therefore unlikely to revert and cause pathological effects. They contain dead virus, incapable of infecting people but still able to instruct the immune system to mount a defensive reaction against an infection,” stated Bharat Biotech, which has developed Covaxin indigenously in collaboration with ICMR.
Covaxin is among three COVID vaccines being used in India’s inoculation drive, Covishield and Russian Sputnik V being the others.
Berhampur: Rushikulya river mouth in Odisha’s Ganjam district has emerged as a major rookery for… Read More
Delhi/Mumbai: Twin tragedies in Delhi and Mumbai claimed the lives of a pair of 18-month-old… Read More
Jajpur: A total of 894 ineligible people fraudulently received benefits under an old-age pension scheme… Read More
Bhubaneswar: The International Conference on Recent Advances in Nanomedicine brought together more than 500 participants,… Read More
New Delhi: In a recent statement that has stirred political conversations, Shashi Tharoor reaffirmed his… Read More
Bhopal: Prime Minister Narendra Modi lashed out at critics of the Mahakumbh Mela at a… Read More
This website uses cookies.
